PRESS RELEASE 2010

• Extension study with FIRMAGON® (degarelix) showed continued benefits for prostate cancer patients beyond one year

Data recently presented on FIRMAGON® (degarelix) hormonal therapy for prostate cancer showed that long-term use beyond one year…

• Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc.

Ferring Pharmaceuticals today announced an agreement that will expand its Women’s Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical’s LYSTEDA™…

• Consider the “whole-man” when treating prostate cancer

Healthcare professionals need to consider the impact of prostate cancer on the ‘whole man’ rather than focusing on cancer treatment in isolation, according to results from an international survey of prostate cancer patients and their partners…

• Wake Up to Nocturia Studies Reinforce Serious Associated Risk of Nocturia

Study results discussed today at the European Association of Urology (EAU) Congress in Barcelona, have reinforced the association between nocturia and a greater risk of falls and mortality…

• Xanodyne and Ferring announce co-promote for ZIPSOR™

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management…